Skip to main navigation Skip to search Skip to main content

Targeted Metabolomics as a Tool in Discriminating Endocrine from Primary Hypertension

  • Zoran Erlic
  • , Parminder Reel
  • , Smarti Reel
  • , Laurence Amar
  • , Alessio Pecori
  • , Casper K. Larsen
  • , Martina Tetti
  • , Christina Pamporaki
  • , Cornelia Prehn
  • , Jerzy Adamski
  • , Aleksander Prejbisz
  • , Filippo Ceccato
  • , Carla Scaroni
  • , Matthias Kroiss
  • , Michael C. Dennedy
  • , Jaap Deinum
  • , Katharina Langton
  • , Paolo Mulatero
  • , Martin Reincke
  • , Livia Lenzini
  • Anne Paule Gimenez-Roqueplo, Guillaume Assié, Anne Blanchard, Maria Christina Zennaro, Emily Jefferson, Felix Beuschlein*
*Corresponding author for this work
  • University of Zurich
  • University of Dundee
  • Université Paris Cité
  • Hôpital européen Georges Pompidou
  • University of Turin
  • Technische Universität Dresden
  • Helmholtz Zentrum München - German Research Center for Environmental Health
  • Technical University of Munich
  • National University of Singapore
  • Cardinal Stefan Wyszynski Institute of Cardiology
  • University of Padua
  • University of Würzburg
  • Ludwig Maximilian University of Munich
  • University of Galway
  • Radboud University Nijmegen
  • Université Paris 5

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

Context: Identification of patients with endocrine forms of hypertension (EHT) (primary hyperaldosteronism [PA], pheochromocytoma/paraganglioma [PPGL], and Cushing syndrome [CS]) provides the basis to implement individualized therapeutic strategies. Targeted metabolomics (TM) have revealed promising results in profiling cardiovascular diseases and endocrine conditions associated with hypertension. Objective: Use TM to identify distinct metabolic patterns between primary hypertension (PHT) and EHT and test its discriminating ability. Methods: Retrospective analyses of PHT and EHT patients from a European multicenter study (ENSAT-HT). TM was performed on stored blood samples using liquid chromatography mass spectrometry. To identify discriminating metabolites a "classical approach"(CA) (performing a series of univariate and multivariate analyses) and a "machine learning approach"(MLA) (using random forest) were used. The study included 282 adult patients (52% female; mean age 49 years) with proven PHT (n = 59) and EHT (n = 223 with 40 CS, 107 PA, and 76 PPGL), respectively. Results: From 155 metabolites eligible for statistical analyses, 31 were identified discriminating between PHT and EHT using the CA and 27 using the MLA, of which 16 metabolites (C9, C16, C16:1, C18:1, C18:2, arginine, aspartate, glutamate, ornithine, spermidine, lysoPCaC16:0, lysoPCaC20:4, lysoPCaC24:0, PCaeC42:0, SM C18:1, SM C20:2) were found by both approaches. The receiver operating characteristic curve built on the top 15 metabolites from the CA provided an area under the curve (AUC) of 0.86, which was similar to the performance of the 15 metabolites from MLA (AUC 0.83). Conclusion: TM identifies distinct metabolic pattern between PHT and EHT providing promising discriminating performance.

Original languageEnglish
Pages (from-to)1111-1128
Number of pages18
JournalJournal of Clinical Endocrinology and Metabolism
Volume106
Issue number4
Early online date16 Feb 2021
DOIs
Publication statusPublished - 1 Apr 2021
Externally publishedYes

Bibliographical note

We thank all participating centers from the ENSAT-HT consortium contributing to the patient recruitment. We thank Julia Scarpa, Werner Römisch-Margl, and Silke Becker for metabolomics measurements performed at the Helmholtz Zentrum München, Genome Analysis Center, Metabolomics Core Facility.

Data Availability Statement

Data generated or analyzed during this study are included in this published article or in the data repositories listed in References. Some datasets generated during and/or analyzed during the current study are not publicly accessible but are available from the corresponding author on reasonable request.

Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 633983 (ENSAT-HT to all authors, except M.D.), by the Clinical Research Priority Program of the University of Zurich for the CRPP HYRENE (to F.B.), and the Deutsche Forschungsgemeinschaft project number 314061271 (CRC/Transregio 205/1 “The Adrenal: Central relay of health and disease” to G.E., M.K., M.R., F.B.).

FundersFunder number
Horizon 2020 Framework Programme633983
Deutsche Forschungsgemeinschaft314061271

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • arterial hypertension
    • Cushing syndrome
    • pheochromocytoma
    • primary aldosteronism
    • screening
    • targeted metabolomics
    • Diagnostic Techniques, Endocrine
    • Humans
    • Middle Aged
    • Cushing Syndrome/complications
    • Male
    • Adrenal Gland Neoplasms/complications
    • Endocrine System Diseases/diagnosis
    • Hyperaldosteronism/diagnosis
    • Hypertension/classification
    • Adult
    • Female
    • Retrospective Studies
    • Pheochromocytoma/complications
    • Diagnosis, Differential
    • Europe
    • Essential Hypertension/diagnosis
    • Aged
    • Metabolomics/methods
    • Paraganglioma/complications

    Fingerprint

    Dive into the research topics of 'Targeted Metabolomics as a Tool in Discriminating Endocrine from Primary Hypertension'. Together they form a unique fingerprint.

    Cite this